NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00054-3722-50 | 00054-3722 | Prednisone | Prednisone | 5.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 13, 1996 | In Use | |
00143-9740-10 | 00143-9740 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 3, 2009 | Jun 30, 2022 | No Longer Used |
00093-0233-93 | 00093-0233 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 21, 2010 | Aug 31, 2013 | No Longer Used | |
63187-0065-30 | 63187-0065 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2014 | In Use | |
45865-0563-30 | 45865-0563 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 1, 2015 | In Use | |
00555-0872-01 | 00555-0872 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 2.5 mg/1 | Hormonal Therapy | Progestin | Oral | Dec 4, 1996 | Jan 26, 2011 | In Use | |
65597-0504-04 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Jul 20, 2023 | In Use | |
00069-1751-30 | 00069-1751 | Talazoparib | Talzenna | 0.75 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jan 31, 2022 | Nov 30, 2025 | In Use |
68382-0826-77 | 68382-0826 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 3, 2018 | Dec 5, 2019 | In Use | |
00069-0296-30 | 00069-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | Jan 31, 2027 | In Use |
72789-0475-21 | 72789-0475 | PredniSONE | PredniSONE Tablets, USP, 10 mg | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 24, 2025 | In Use | |
16714-0522-10 | 16714-0522 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sep 19, 2012 | Aug 31, 2014 | No Longer Used | |
51862-0458-47 | 51862-0458 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Jul 18, 2016 | In Use | |
63629-6659-01 | 63629-6659 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 10, 2015 | Aug 31, 2018 | No Longer Used |
63561-0121-01 | 63561-0121 | PredniSONE | PredniSONE Tablets, USP, 10 mg | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 22, 2025 | In Use | |
59572-0215-93 | 59572-0215 | Thalidomide | Thalomid | 150.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 20, 2007 | In Use | |
00615-8441-39 | 00615-8441 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 10, 2022 | In Use | |
42388-0024-37 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb 27, 2019 | In Use | |
69189-0464-01 | 69189-0464 | Tretinoin | Tretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan 8, 2016 | May 24, 2017 | No Longer Used |
70518-2314-02 | 70518-2314 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 19, 2020 | In Use | |
82009-0112-12 | 82009-0112 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 21, 2023 | In Use | |
00527-2935-37 | 00527-2935 | Prednisone | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 4, 2018 | Apr 30, 2023 | No Longer Used |
60505-3802-07 | 60505-3802 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
71335-1424-02 | 71335-1424 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec 28, 2021 | In Use | ||
62756-0131-02 | 62756-0131 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use |
Found 11765 results — Export these results